Article ; Online: The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.
2022 Volume 11, Issue 18
Abstract: 1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that target the anti-PD-1 immune checkpoint. However, only about 20% of the ... ...
Abstract | (1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that target the anti-PD-1 immune checkpoint. However, only about 20% of the patients display a long-lasting objective tumor response. The modulation of cancer cell immunogenicity via a treatment-induced immunogenic cell death is proposed to potentially be able to improve the rate of patients who respond to immune checkpoint blocking immunotherapies. (2) Methods: Using human HNSCC cell line models and a mouse oral cancer syngeneic model, we have analyzed the ability of the EXTREME regimen (combination therapy using the anti-EGFR cetuximab antibody and platinum-based chemotherapy) to modify the immunogenicity of HNSCC cells. (3) Results: We showed that the combination of cetuximab and cisplatin reduces cell growth through both cell cycle inhibition and the induction of apoptotic cell death independently of p53. In addition, different components of the EXTREME regimen were found to induce, to a variable extent, and in a cell-dependent manner, the emission of mediators of immunogenic cell death, including calreticulin, HMGB1, and type I Interferon-responsive chemokines. Interestingly, cetuximab alone or combined with the IC |
---|---|
MeSH term(s) | Animals ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Apoptosis ; Calreticulin ; Cetuximab/therapeutic use ; Cisplatin/therapeutic use ; HMGB1 Protein ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/immunology ; Humans ; Immunity ; Interferon Type I ; Mice ; Neoplasm Recurrence, Local/pathology ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Tumor Suppressor Protein p53 |
Chemical Substances | Calreticulin ; HMGB1 Protein ; Interferon Type I ; Tumor Suppressor Protein p53 ; Cetuximab (PQX0D8J21J) ; Cisplatin (Q20Q21Q62J) |
Language | English |
Publishing date | 2022-09-14 |
Publishing country | Switzerland |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2661518-6 |
ISSN | 2073-4409 ; 2073-4409 |
ISSN (online) | 2073-4409 |
ISSN | 2073-4409 |
DOI | 10.3390/cells11182866 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.